Personal profile
Personal profile
Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.
Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.
Research interests
Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.
Education/Academic qualification
PhD, University of Cambridge
Free-text keywords
- Cell therapy
- Gene therapy
- Stem cells
- Vectors
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
Musher, B. L., Vasileiou, S., Smaglo, B. G., Robertson, C. S., Wu, M., Wang, T., Watanabe, A., Kuvalekar, M., Velazquez, Y., Ketkar, S., Doheyan, T. A., Papayanni, P. G., Shah, A., Lapteva, N., Grilley, B. J., Van Buren, G., Lulla, P. D., Heslop, H. E., Rooney, C. M. & Brenner, M. K. & 1 others, , Jan 2026, In: Nature Medicine. 32, 1, p. 258-269 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Editorial Expression of Concern: E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells(Cancer Gene Therapy, (2024), 10.1038/sj.cgt.7700739)
Rao, X. M., Tseng, M. T., Zheng, X., Dong, Y., Jamshidi-Parsian, A., Thompson, T. C., Brenner, M. K., McMasters, K. M. & Zhou, H. S., Jan 2025, In: Cancer Gene Therapy. 32, 1, p. 147 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., Masand, P., Maris, J. M., Martinez, D., Pogoriler, J., Varadarajan, N., Thakkar, S. G., Lyon, D., Lapteva, N., Zhuyong, M. & Patel, K. & 12 others, , Jan 23 2025, In: Nature. 637, 8047, p. 940-946 7 p.Research output: Contribution to journal › Article › peer-review
Open Access157 Link opens in a new tab Scopus citations -
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
Li, C. H., Sharma, S., Heczey, A. A., Woods, M. L., Steffin, D. H. M., Louis, C. U., Grilley, B. J., Thakkar, S. G., Wu, M., Wang, T., Rooney, C. M., Brenner, M. K. & Heslop, H. E., Feb 17 2025, (E-pub ahead of print) In: Nature Medicine. 31, 4, p. 1125-1129 5 p.Research output: Contribution to journal › Article › peer-review
37 Link opens in a new tab Scopus citations -
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
Hill, L. Q. C., Rouce, R. H., Wu, M. J., Wang, T., Ma, R., Zhang, H., Mehta, B., Lapteva, N., Mei, Z., Smith, T. S., Yang, L., Srinivasan, M., Burkhardt, P. M., Ramos, C. A., Lulla, P., Arredondo, M., Grilley, B., Heslop, H. E., Brenner, M. K. & Mamonkin, M., Mar 28 2024, In: Blood. 143, 13, p. 1231-1241 11 p.Research output: Contribution to journal › Article › peer-review
52 Link opens in a new tab Scopus citations